Newron Pharmaceutical Forecast, price target & analysts
Newron Pharmaceutical Target price 2025 - Analyst rating & recommendation
Newron Pharmaceutical Classifications & Recommendation:
Newron Pharmaceutical Price Target
| Target Price | CHF13.06 |
| Price | CHF10.70 |
| Potential |
22.02%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Newron Pharmaceutical 2026 .
The average Newron Pharmaceutical target price is CHF13.06.
This is
22.02%
register free of charge
CHF26.25
145.33%
register free of charge
CHF11.62
8.55%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Newron Pharmaceutical to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Newron Pharmaceutical stock has an average upside potential 2026 of
22.02%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 48.00 | 12.57 |
| 467.38% | 73.82% | |
| EBITDA Margin | 51.31% | -209.19% |
| 140.68% | 507.68% | |
| Net Margin | 30.83% | -250.17% |
| 117.22% | 911.36% |
5 Analysts have issued a sales forecast Newron Pharmaceutical 2025 . The average Newron Pharmaceutical sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Newron Pharmaceutical EBITDA forecast 2025. The average Newron Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Newron Pharmaceutical Analysts have issued a net profit forecast 2025. The average Newron Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 0.80 | -1.58 |
| 194.12% | 297.50% | |
| P/E | negative | |
| EV/Sales | 19.54 |
5 Analysts have issued a Newron Pharmaceutical forecast for earnings per share. The average Newron Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Newron Pharmaceutical...
Current Newron Pharmaceutical Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | May 12 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | May 11 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
May 12 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
May 11 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Mar 31 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
